Benfotiamine

Benfotiamine, chemically S-benzoylthiamine O-monophosphate, is a synthetic S-acyl derivative of thiamine, better known as vitamin B1 ^[1]. It belongs to a family of lipid-soluble thiamine precursors developed to overcome a limitation of ordinary thiamine: the water-soluble vitamin is absorbed only to a limited degree, whereas benfotiamine's fat-soluble design lets it reach higher concentrations in the blood and in tissues such as muscle, nerve, liver, and kidney ^[1]. After it is taken by mouth, benfotiamine is dephosphorylated by an enzyme (ecto-alkaline phosphatase) to lipid-soluble S-benzoylthiamine, which is then converted into thiamine inside the body ^[1].

The rationale for benfotiamine rests on the role of thiamine diphosphate, the active form of the vitamin, as a cofactor for transketolase, an enzyme of glucose metabolism ^[1]. By raising intracellular thiamine diphosphate, benfotiamine increases transketolase activity, which diverts the buildup of harmful glucose byproducts into the safer pentose phosphate pathway ^[1][2]. This is thought to reduce the formation of advanced glycation end products, the sugar-damaged proteins that accumulate in poorly controlled diabetes and drive many of its complications, and to curb related damaging routes such as the polyol, hexosamine, and protein kinase C pathways ^[2].

Benfotiamine's main established use is in diabetic sensorimotor polyneuropathy, the nerve damage of diabetes, where clinical studies have reported reductions in neuropathic symptoms, and it is often reviewed alongside alpha-lipoic acid as a pathogenetically oriented treatment ^[2]. Laboratory and animal research has extended interest to other diabetic complications of the kidney (nephropathy), eye (retinopathy), and blood vessels, and has documented direct antioxidant and anti-inflammatory actions that appear to be independent of thiamine's classic coenzyme role ^[3][4]. More recently, benfotiamine and related thiamine thioesters have been studied for neuroprotection, including early clinical work in mild Alzheimer's disease ^[4]. Reviewers generally conclude that while the findings are encouraging, larger and more definitive trials are still needed ^[2][4].

Regulatory status varies by country: benfotiamine is marketed as an over-the-counter drug in several places, often under brand names such as Milgamma and Benfogamma and frequently combined with other B vitamins, while in the United States it is sold as a dietary supplement rather than an approved drug ^[1]. It is generally well tolerated, with only minor side effects such as mild nausea or stomach upset reported in a small fraction of users, and it is taken orally, most commonly as tablets ^[1].

It is sold as a supplement in many countries and has an excellent safety record; trials in diabetics report tolerability similar to placebo. Being a B1 derivative it is low-toxicity, with only occasional mild GI complaints. Worth noting it is more peripheral than central, so it is a poor pick if your goal is specifically brain thiamine; TTFD or sulbutiamine fit that better.